Peng X.-F.,Longgang District Central Hospital of Shenzhen City |
Jiang W.-H.,Longgang District Central Hospital of Shenzhen City |
Yan J.,Longgang District Central Hospital of Shenzhen City |
Deng J.-T.,Longgang District Central Hospital of Shenzhen City
International Eye Science | Year: 2014
AIM: To explore the curative effect of methylprednisolone with octreotide retrobulbar injection therapy on thyroid associated ophthalmopathy.METHODS: Fifty-one cases (96 eyes) with thyroid associated ophthalmopathy were treated with methylprednisolone (500mg/d) for 3d, and then retrobulbar injection of octreotide (0.1mg/mo) for 3mo in one course. Symptoms and signs of the patients were observed before and after the treatment course.RESULTS: Symptoms of 49 cases were improved significantly. In all cases, the mean value of exophthalmus of the patients was significantly decreased after the treatment by 3.1±1.4mm. The height of palpebral fissure was significantly decreased after the treatment by 2.4±0.9mm, there were statistically significant difference before and after treatment (P<0.05).CONCLUSION: Methylprednisolone with octreotide retrobulbar injection therapy can improve symptoms and signs of the patients with thyroid associated ophthalmopathy with high safety and no obvious side effect.
Gao T.,Longgang District Central Hospital of Shenzhen City |
Wu D.,Longgang District Central Hospital of Shenzhen City |
Zhang H.,Longgang District Central Hospital of Shenzhen City |
Xu Z.,Longgang District Central Hospital of Shenzhen City |
And 3 more authors.
Chinese Journal of Radiology (China) | Year: 2015
Objective: To evaluate the clinical efficacy of interventional techniques in the diagnosis and therapy of Dieulafoy disease. Methods: A retrospective study was performed, including 17 patients with massive upper gastrointestinal hemorrhage (patients without peptic ulcer and portal hypertension or diagnosed with Dieulafoy disease by endoscopic examination). All patients had both DSA and interventional embolization treatment, and were followed for 12 months to appraise the clinical effectiveness. Results: Sixteen patients were diagnosed as Dieulafoy disease by using DSA. Fifteen of the 16 patients were treated with embolization successfully withoutserious complications. One patient received subtotal gastrectomy because of upper gastrointestinal hemorrhage recurrence. Nine patients with irregular upper abdominal pain and burning sensation had complete remission after symptomatic management. Fifteen patients who had embolization showed no serious complications during the follow-up period of 12 months, there was no hematemesis and melena for the 15 cases with successful embolization. Conclusion: The angiography and embolization are safe and efficacious in the diagnosis and therapy of Dieulafoy disease. Copyright © 2015 by the Chinese Medical Association.
Zhou X.-L.,Central South University |
Zhou X.-L.,Longgang District Central Hospital of Shenzhen City |
Deng H.-Y.,Central South University |
Li X.-H.,Central South University |
And 2 more authors.
Chinese Journal of Medical Imaging Technology | Year: 2011
Objective: To evaluate the imaging characteristics of 18F-FDG PET/CT in non-small-cell lung cancer (NSCLC) patients, and to investigate the correlation between the expression level of vascular endothelial growth factor (VEGF) in NSCLC tissue and 18F-FDG uptake. Methods: Forty patients with NSCLC (NSCLC group) and 15 patients with benign lesions (benign group) underwent 18F-FDG PET/CT imaging of the whole body before operation. Tumor tissue were obtained after operation to evaluate the VEGF expression. The level of VEGF expression was measured, and the Mattern half-quantitative analysis was taken to score VEGF expression of the lump tissue. Standardized uptake value (SUV) of all patients were measured on PET/CT imaging, and SUV of benign lesions and different types of malignant lesions of lung were compared. The levels of VEGF expression in the benign and malignant lesions were scored, and the correlation between VEGF expression of NSCLC tissue and SUV of the correspondent patient was analyzed statistically. Results: SUV of NSCLC group (5.03±2.89) was higher than that of benign group (2.05±0.63). There was no difference among different pathological types of NSCLC (all P>0.05). There was statistical difference of SUV in NSCLC between <2.0 cm and ≥4.0 cm, as well as of VEGF expression among tuberculoma, squamous cell carcinoma and adenocarcinoma (all P<0.05). There was significant correlation between VEGF expression and SUV (r=0.478, P<0.01) of NSCLC. The score of the VEGF expression was significantly higher in patients with metastasis and/or recurrence (n=7) than in patients with no metastasis and/or recurrence (n=11) 6 months after operation. Conclusion: The determination of SUV may be helpful to predict the status of vascular proliferation in carcinoma tissue of NSCLC patients.